 |
BioMedicure won the San Diego Outstanding Enterprise Award in 2014.BioMedicure won the San Diego Outstanding Enterprise Award in 2014 (for two consecutive years receiving the Outstanding Biochemical Laboratory Enterprise Award). BioMedicure successfully used the ATATES™ patented product to help many late-stage cancer patients, including those with pancreatic cancer, liver cancer, esophageal cancer, colorectal cancer, lung cancer, thyroid cancer, multiple myeloma, melanoma, lymphoma, breast cancer, and ovarian cancer. Ten patients cured of their cancer using the ATATES™ new antigen patented product lived for two years without disease in 2014! |
 |
BioMedicure won the San Diego Outstanding Enterprise Award in 2015.BioMedicure won the San Diego Outstanding Enterprise Award in 2015 (for three consecutive years receiving the Outstanding Enterprise Award). BioMedicure successfully used the ATATES™ patented product to help various late-stage cancer patients, including those with pancreatic cancer, liver cancer, esophageal cancer, colorectal cancer, lung cancer, thyroid cancer, multiple myeloma, melanoma, lymphoma, breast cancer, and ovarian cancer.Ten patients cured of their cancer using the ATATES™ new antigen patented product lived for three years without disease in 2015! |
 |
BioMedicure won the San Diego Outstanding Enterprise Award in 2016.BioMedicure won the San Diego Famous Enterprise Award in 2016 (for four consecutive years receiving the Outstanding Enterprise Award for Biological Laboratories). BioMedicure successfully used the ATATES™ patented product to help various late-stage cancer patients, including those with pancreatic cancer, liver cancer, esophageal cancer, colorectal cancer, lung cancer, thyroid cancer, multiple myeloma, melanoma, lymphoma, breast cancer, and ovarian cancer. Ten patients cured of their cancer using the ATATES™ new antigen patented product lived for four years without disease in 2014! |
 |
BioMedicure won the San Diego Outstanding Enterprise Award in 2017.BioMedicure won the San Diego Famous Enterprise Award in 2017 (for five consecutive years receiving the Outstanding Enterprise Award for Biological Laboratories). BioMedicure successfully used the ATATES™ patented product to help various late-stage cancer patients, including those with pancreatic cancer, liver cancer, esophageal cancer, colorectal cancer, lung cancer, thyroid cancer, multiple myeloma, melanoma, lymphoma, breast cancer, and ovarian cancer. Ten patients cured of their cancer using the ATATES™ new antigen patented product lived for five years without disease in 2017! |
 |
BioMedicure won the San Diego Outstanding Enterprise Award in 2018.BioMedicure won the San Diego Famous Enterprise Award in 2018 (for five consecutive years receiving the Outstanding Enterprise Award for Biochemical Laboratories). This is a high recognition for the inventions of BioMedicure.The ATATES™ and AMAMES™ new antigen patented products are highly recognized. The ATATES™ and AMAMES™ new antigen patented products customized for eligible clients feature 100% targeting of genomic variations, multiple effective ingredients, various therapeutic effects, long-term efficacy, product efficacy superposition for different treatment courses, and adherence to the special rules of the immune system without any toxic side effects on normal cells, tissues, organs, and systems. Ten patients cured of their cancer using the ATATES™ new antigen patented product lived for six years without disease. |
 |
Chairman Qian Yong was awarded the "Top Ten Innovators of China in 2017."Chairman Qian Yong was awarded the "Top Ten Innovators of China in 2017" for leading the BioMedicure and BioMedicure (Shanghai) Medical Research Co., Ltd. team to use the ATATES™ patented product to help many late-stage cancer patients (of which ten cancer patients lived for five years without disease) and to use the AMAMES™ patented product to assist many sub-healthy, infected, and difficult-to-treat disease patients. |
 |
Chairman Qian Yong was awarded the "Outstanding Innovative Entrepreneur of China in 2017."Chairman Qian Yong was awarded the "Outstanding Innovative Entrepreneur of China in 2017" for successfully leading the BioMedicure team to use the ATATES™ new antigen product to rescue many late-stage and terminal cancer patients (of which ten have lived without disease for over five years) and to use the AMAMES™ patented product to assist many sub-healthy, infected, and difficult-to-treat disease patients. |
 |
BioMedicure (Shanghai) Medical Research Co., Ltd. collaborates with CCTV's "Credit China" program team, dedicated to "using credible products to enhance human ability to prevent and treat various diseases," customizing new antigen products for eligible cancer, tumor, infection, sub-healthy, and difficult-to-treat disease patients, allowing their immune systems to upgrade according to the new antigens, immune-clear cancer cells and their derivatives, tumor cells, sources of infection, and mutated cells with new antigens, and preventing recurrence to achieve long-term health. |
 |
"Integrity China" EnterpriseBioMedicure (Shanghai) Medical Research Co., Ltd. was rated as a "Credit Recognized Enterprise" by the Credit Rating and Certification Center of the Ministry of Commerce's International Economic Cooperation Research Institute. The new antigen products invented by BioMedicure utilize the natural law that a person's immune system can continuously upgrade according to new antigens, targeting the cause 100% and having 0% toxic side effects, which is the basis for credit recognition. |
 |
Chairman Qian Yong attended the "Fourth Eastern Economic Forum."Chairman Qian Yong was invited by the China-Europe Economic and Technological Cooperation Association to attend the "Fourth Eastern Economic Forum" themed on the forum of leaders from five countries including President Putin and President Xi Jinping. |
 |
Chairman Qian Yong attended the "Ninth World Gene Conference."Chairman Qian Yong accepted the invitation from the organizing committee to attend the "Ninth World Gene Conference" held in Singapore from November 13-15, 2018, and gave a speech on "New Antigen Treatment of Various Diseases Including Cancer Based on Genomics." |
Tel: 021-50815370
Fax: 021-50815370
E-mail: admin@biomedicure.com
Address: Building 2, Lane 720, Cai Lun Road, and Building 10, Lane 198, Zhang Heng Road, China (Shanghai) Pilot Free Trade Zone
Pay attention to WeChat public number
Payment Scan Code Registered Member
See more in-station information